Previously, the similar oncogenic roles of TSPEAR-AS2 on gastric cancer cells were also demonstrated, suggesting the great potential of TSPEAR-AS2 used as a novel therapeutic target [17]. This evidence concerns the gene TSPEAR and gastric cancer.